Rapid synthesis and novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistry

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 16, 1996, Pages 1905-1910

  Foley, Michael A ^a,b   Hassman, Angela S ^a   Drewry, David H ^a   Greer, David G ^a   Wagner, Craig D ^a   Feldman, Paul L ^a   Berman, Judd ^a   Bickett, D Mark ^a   McGeehan, Gerry M ^a   Lambert, Millard H ^a   Green, Michael ^a  

^a GLAXOSMITHKLINE   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; DIPEPTIDE; ENZYME INHIBITOR; GELATINASE;

ARTICLE; CHIRALITY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; PEPTIDE SYNTHESIS; STRUCTURE ACTIVITY RELATION; TECHNIQUE;

EID: 0030594987     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00333-2     Document Type: Article

References (21)

1. 1 Address for correspondence: Harvard University, Department of Chemistry, 12 Oxford St., Cambridge, MA 02138.
2. 2 (a) Borkakoti, N.; Winkler, F. K.; Williams, D. H.; D'Arcy, A.; Broahhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J.Nature struct. Biol. 1994,1, 106.
3. (b) Gooley, P. R.; O'Connell, J. F.; Marcy, A. I.; Cuca, G. C.; Salowe, S. P.; Bush, B. L.; Hermes, J. D.; Esser, C. K.; Hagmann, W. K.; Spurlino, J. C.; Smith, D. L.; Wahl, R. C.; Ho, T. F.; Qoronfleh, M. O.; Banks, T. M.; Rubin, B. Nature struct. Biol. 1994, 1, 119.
4. (d) Lovejoy, B.; Cleasby, A. C.; Hassell, A. M.; Longely, K.; Luther, M. A.; Weigl, D. A.; McGeehan, G.; McElroy, A. B.; Drewry, D. H.; Lambert, M. H., Jordan, S. Science 1994, 263, 375.
5. 3 Bode, W.; Gomis-Ruth, F. X.; Stocker, W. FEBS Lett. 1993, 331, 134.
6. 4 (a) Docerty, A. J.; Murphy, G. Ann. Rheum. Dis. 1990, 49, 469.
7. (b) Johnson W. H. ; Borkakoti, N. J. Enzyme Inhib. 1987, 2, 1.
8. (c) Harper, G. P. European Patent No. 423,943, 1991.
9. 5 (a) Johnson W. H. ; Borkakoti, N. J. Enzyme Inhib. 1987, 2, 1.
10. (b) Henderson, B.; Docerty, A. J.; Beeley, N. R.; Drugs Future 1990, 15, 495.
11. (c) Shwartz, M. A.; Van Wart, H. E. Progress in Medicinal Chemistry; Ellis, G. P.; Luscombe, D. K., Eds.; Elsevier Science : The Netherlands, 1992, Vol. 29.
12. (d) Emonard, H.; Grimaud, H. Cell. Mol. Biol. 1990, 36, 131.
13. (e) Wahl, R. C.; Dunlap, R. P.; Morgan, B. P. Annual Reports in Medicinal Chemistry; Academic: New York, 1989; Vol. 25.
14. (f) Rich, D. H. Comprehensive Medicinal Chemistry; Hansch, C.; Sammes, P. G., Taylor, J. B., Eds.; Pergamon: New York, 1990.
15. 6 The Glaxo Wellcome compound portfolio was not screened against gelatinase.
16. 7 (a) Brown, F. A.; Brown, P. J.; Bickett, D. M.; Chambers, C. L.; Davies, H. G.; Deaton, D. N.; Drewry, D. H.; Foley, M. A.; McElroy, A. B.; Gregson, M.; McGeehan, G.; Myers, P. L.; Norton, D.; Salovich, J. M.; Schoenen, F. J.; Ward, P. J. J. Med. Chem. 1994, 37, 674.
17. (b) Bickett, D. M.; Green, M. D.; Berman, J.; Dezube, M.; Howe, A. S.; Brown, P. J.; Roth, J. T.; McGeehan, G. M. Anal. Biochem. 1993, 212, 58.
18. 8 This series was not assayed against gelatinase.
19. 9 Lambert, M. H. Computer-Assisted Modeling in Molecular Pharmacology, Charifson, P. S. Ed.; Marcel Dekker; New York , In Press.
20. 10 Shimoni, L.; Glusker, J. P.; Bock, C. W. J.Physical Chem. 1995, 99, 1194.
21. 11 Browner, M. F., Personal Communication.